Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to determine if armodafinil treatment, at a dosage of
150 mg/day, is more effective than placebo treatment as adjunctive therapy for adults who are
experiencing a major depressive episode associated with Bipolar I Disorder and who are
inadequately responsive to their current treatment for a current major depressive episode.